Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02787044 · ClinicalTrials.gov registry record · Phase 4
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
A Phase 4 study of Heart Failure and Myocardial Infarction, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 5,388
- Enrollment target
- 20
- Study locations
NCT02787044: Completed Phase 4 study of Heart Failure and Myocardial Infarction, sponsored by Brigham and Women's Hospital.
NCT02787044 is a Phase 4 study of Heart Failure and Myocardial Infarction that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 5,388 participants, above the 2,035-participant average among 397 other Heart Failure trials with a reported enrollment target (165% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02787044, a Phase 4 study of Heart Failure and Myocardial Infarction, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5,388 participants
- Enrollment target
- 20
- Study locations
Study Summary
INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.
Primary Outcome
Number of patients with first occurrence of death or cardiopulmonary hospitalization within each vaccination season
Conditions Studied
Interventions
- BIOLOGICAL High Dose Trivalent Influenza Vaccine
- BIOLOGICAL Standard Dose Quadrivalent Influenza Vaccine
Study Locations (20)
Florida
- Clearwater Cardiovascular Consultants - Clearwater
- N FL/S GA Veterans Health System - Gainesville
- OneFlorida CDRN - Gainesville
- Clearwater Cardiovascular Consultants-Largo - Largo
- Inpatient Research Corporation - Miami
- ITB Research - Miami
California
- VA Loma Linda Healthcare System - Loma Linda
- Long Beach VAMC - Long Beach
- University of California Davis Medical Center - Sacramento
- VA San Diego Healthcare System - San Diego
- UCSF Medical Center - San Francisco
Alabama
- Birmingham VAMC - Birmingham
- University of Alabama Hypertension Program - Birmingham
- Heart Center Research, LLC - Huntsville
Arizona
- Banner University Medicine North - Tucson
- University of Arizona- Sarver Heart Center - Tucson
Alaska
- Alaska Heart & Vascular Institute - Anchorage
Arkansas
- CAVHS - Little Rock
Connecticut
- VA West Haven - West Haven
District of Columbia
- Washington DC VAMC - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,388 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2020-05-31 |
| Phase | Phase 4 |
What the finished NCT02787044 record still lists
NCT02787044 is an interventional study that assigns participants to a tested intervention. Its 5,388 participants enrollment target places it among the larger protocols in the corpus, above the 2,035-participant average among 397 other Heart Failure trials with a reported enrollment target (165% higher).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which High Dose Trivalent Influenza Vaccine is the first listed.
NCT02787044 names 20 study sites across 8 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT02787044 about?
NCT02787044 is a clinical study titled "INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure". INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will e...
What is the current status of trial NCT02787044?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5,388 participants. The study started on 2016-08-01. Estimated completion is 2020-05-31.
What conditions does trial NCT02787044 study?
This clinical trial studies the following conditions: Heart Failure, Myocardial Infarction.
What interventions are being tested in trial NCT02787044?
The interventions under investigation include: High Dose Trivalent Influenza Vaccine (BIOLOGICAL), Standard Dose Quadrivalent Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02787044?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02787044 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02787044's enrollment target sits among peer trials
5,388 17th of 397 higher than 381 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
RECRUITING · Phase 4
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RECRUITING · Phase 4
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722769 · 5,408 participants · NA
CSTOP Now! Child Sex Trafficking Stops With You
- NCT05836987 · 5,350 participants · Phase 3
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- NCT05373771 · 5,328 participants · NA
Sickle Cell Improvement: Enhancing Care in the Emergency Department
- NCT04295486 · 5,478 participants · Phase 2
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI